Efficacy and safety of sedative agents for endoscopic submucosal dissection of esophageal carcinoma

Efficacy and safety of sedative agents for endoscopic submucosal dissection of esophageal carcinoma - Efficacy and safety of sedative agents for endoscopic submucosal dissection of esophageal carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024561

Enrollment

200

Registered

2016-10-25

Start date

2016-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who have a superficial esophageal cancer treated by endoscopic resection or esophagectomy

Exclusion criteria

Exclusion criteria: Patients whom a researcher judged to be inappropriate as a subject.

Design outcomes

Primary

Measure	Time frame
treatment performance for endoscopic submucosal dissection using midazolam or propofol	—

Countries

Japan

Contacts

Public ContactOsamu Dohi

Kyoto Prefectural University of Medicine Department of Molecular Gastroenterology and Hepatology

osamu-d@koto.kpu-m.ac.jp075-251-5519

Outcome results